Top Stem Cell Therapy Companies

The global stem cell therapy market is expanding significantly for several reasons. One of the underlying drivers of market growth is the increase in funding and support for research and development in the field of stem cell therapy from government programs and private organizations. The formation of strategic partnerships in academia, research institutions, and biopharmaceutical companies will foster the increased creation of new knowledge and resource sharing while expediting research into the clinical application of stem cell therapies. Conversely, there are increasing numbers of clinical trials to assess the safety and efficacy of new treatments due to the rising incidence of chronic and degenerative diseases that will be increase the available treatment options for patients.

Industry Overview

According to SkyQuest Technology “Stem Cell Therapy Market By Therapy (Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy), By Type, By Source, By Route of Administration, By Technology, By Application,  By Region - Industry Forecast 2025-2032,” Global Stem Cell Therapy Market is projected to grow at a CAGR of over 18.70% by 2032, on account of urgent need for automating quantified data. Technological advances in stem cell manufacturing, gene editing and tissue engineering will continue to provide innovations that will make therapies more effective and accessible. Favorable regulatory environments in leading regions will promote innovation and development while enabling more therapies to be manufactured using stem cells, and new development of stem cell derived products.

Top 10 Global Stem Cell Therapy Companies

1. Mesoblast Ltd.

Founded in 2004 in Melbourne, Australia, Mesoblast Ltd. is a prominent company in the field of regenerative medicine. The company develops allogeneic cellular medicines, which are based on its proprietary mesenchymal lineage adult stem cells. The company has a pipeline which targets indications such as chronic heart failure, graft-versus-host disease (GvHD), and inflammatory diseases, helping to define Mesoblast as a key innovator in providing therapies based on large-scale stem cell-based therapies.   

2. Gamida Cell Ltd.

Gamida Cell was established in 1998 in Jerusalem, Israel, and specializes in advanced cellular therapies and immune therapies. The company has developed cell therapies for treating cancers and rare genetic diseases, with a focus on hematological and oncology areas. Its first commercialized cell therapy, Omisirge (omidubicel-onlv), received FDA approval in 2023, defining the company as an innovative leader in this fast-moving field of commercialized therapies based on stem cells.    

3. BrainStorm Cell Therapeutics

Founded in 2000 and headquartered in New York, USA, BrainStorm Cell Therapeutics develops autologous adult stem cell therapies to treat neurodegenerative diseases. The company's proprietary technology, NurOwn®, utilizes mesenchymal stem cells (MSCs) to secrete neurotrophic factors believed to promote the treatment of diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). Although Brainstorm remains in the pre-commercialized stage of its therapies, it is well-recognized for its strong emphasis on the neurological application of adult stem cell therapies.

4. Cynata Therapeutics Ltd.

Cynata Therapeutics, established in Melbourne, Australia in 2003, is a clinical-stage company employing induced pluripotent stem cell (iPSC) technology. Its proprietary Cymerus™ platform is able to produce MSCs at scale for multiple therapeutic applications. Cynata is advancing clinical programs in osteoarthritis, critical limb ischemia, and graft-versus-host disease, reflecting the potential versatility of the company’s iPSC-based stem cell innovation. 

5. Pluri Inc. (formerly Pluristem Therapeutics)

Pluri, founded in 2001 in Haifa, Israel, develops cell therapy products derived from placenta. The company employs its proprietary 3D cell expansion technology in the manufacturing of placental cells for potential therapeutic applications in ischemic, inflammatory, and hematologic conditions. Pluri also aims to broaden its potential applications especially around therapeutic intervention by entering new biotechnology innovation platforms, such as cell-based protein manufacturing.

6. Lineage Cell Therapeutics

Lineage Cell Therapeutics, established in 1990 and based in Carlsbad in California, USA, develops regenerative medicine therapies for degenerative diseases. Current studies encompass cell-based therapies for dry age-related macular degeneration, spinal cord injury, and oncology. Lineage will produce certain cell types, derived from pluripotent stem cells, using proprietary manufacturing processes to advance research-based therapy to clinical stage therapy.

7. Vericel Corporation

Vericel Corporation, established in 1989 and based in Cambridge, Massachusetts, USA, develops cell therapy products in the fields of sports medicine and burn care. Vericel’s first product, MACI®, is an autologous cellularized scaffold for the treatment of knee cartilage repair. Vericel’s second product, Epicel®, is a cultured epidermal autograft used for the treatment of the most severe burns.

8. Fate Therapeutics

Fate Therapeutics, founded in 2007 and headquartered in San Diego, California, USA, is a developer of programmed cellular immunotherapies. The company develops therapies to treat cancer and immune disorders using induced pluripotent stem cells (iPSCs), which allows for the development of standardized and off-the-shelf therapies for these conditions.

9. Osiris Therapeutics (Smith+Nephew)

Founded in 1992 as a company in orthopedics, wound care, and inflammatory diseases, Osiris Therapeutics operated out of Columbia, Maryland, USA, and was an early pioneer in regenerative medicine. Following its acquisition by Smith+Nephew, Osiris’s legacy products, Grafix® and Ovation®, remain an important legacy in regenerative medicine.

10. Athersys Inc.

Athersys Inc., founded in 1995 and headquartered in Cleveland, Ohio, USA, develops therapies based on multipotent adult progenitor cell (MAPC) technology. Athersys’s lead product candidate, MultiStem®, is being investigated to treat ischemic stroke, acute respiratory distress syndrome, and other inflammatory or immune-based conditions.

Other Leading Global Stem Cell Therapy Companies

• AstraZeneca
• Amgen
• Gilead Sciences
• Mesoblast Ltd.
• Gamida Cell Ltd.
• BrainStorm Cell Therapeutics
• Cynata Therapeutics
• Pluristem Therapeutics (Pluri Inc.)
• Lineage Cell Therapeutics
• Vericel Corporation
• Sanofi (via Inhibrx)
• Smith+Nephew (via Osiris Therapeutics)

Conclusion

The global stem cell therapy market is set for substantial expansion due to increasing research activities, technological progress and increased demand for innovative therapies for chronic and degenerative diseases. Supporting regulatory activity and increased collaboration between healthcare institutions and biotechnology companies are facilitating the faster development and delivery of such therapies. New and evolving technologies, such as gene editing, 3D bioprinting, induced pluripotent stem cells, and nanotechnology, are increasing the ability of stem cells to therapeutically impact several chronic degenerative disorders while also personalizing and increasing the effectiveness of their treatment.